STOCK TITAN

Bausch + Lomb Corp - BLCO STOCK NEWS

Welcome to our dedicated news page for Bausch + Lomb (Ticker: BLCO), a resource for investors and traders seeking the latest updates and insights on Bausch + Lomb.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Bausch + Lomb's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Bausch + Lomb's position in the market.

Rhea-AI Summary
Bausch + Lomb Corporation to release Q3 2023 financial results on Nov. 1, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.75%
Tags
-
Rhea-AI Summary
Bausch + Lomb to present at AAOpt annual meeting, highlighting the results of a study on Blink Triple Care Lubricating Dry Eye Drops and data on MIEBO prescription eye drops and INFUSE Multifocal contact lenses. Educational events will also be hosted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.89%
Tags
none
-
Rhea-AI Summary
Bausch + Lomb completes acquisition of XIIDRA for $2.5 billion, funded by $1.4 billion senior secured notes and $500 million term B loans.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
Rhea-AI Summary
Bausch + Lomb completes acquisition of XIIDRA and other ophthalmology assets, expects to lead in prescription dry eye category. DED affects 739 million people worldwide, with the US market expected to grow at a double-digit compounded annual growth rate over the next five years. The acquisition was funded through an upfront payment of $1.75 billion in cash, with potential milestone obligations of up to $750 million based on sales thresholds and pipeline commercialization. XIIDRA and MIEBO are prescription eye drops used to treat dry eye disease.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
-
Rhea-AI Summary
Bausch + Lomb launches LUMIFY EYE ILLUMINATIONS, a new line of specialty eye care products. The products are hypoallergenic, clinically proven, and free from harsh ingredients. The line includes a cleansing water and makeup remover, lash & brow serum, and brightening eye cream. Clinical studies show visible improvements in skin tone, texture, and lash volume. The products are available in stores and online.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
none
-
Rhea-AI Summary
Bausch + Lomb's ONE by ONE and Biotrue Eye Care Recycling programs recognized as 2023 Sustainability Award winners
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.37%
Tags
none
Rhea-AI Summary
Bausch + Lomb prices $1.4 billion senior secured notes offering to fund acquisition of XIIDRA® and other ophthalmology assets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.73%
Tags
none
-
Rhea-AI Summary
Bausch + Lomb launches MIEBO, the first prescription eye drop targeting tear evaporation in dry eye disease
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
none
-
Rhea-AI Summary
Bausch + Lomb launches $1.4 billion offering of senior secured notes and seeks to enter into an incremental term loan facility. The proceeds will fund the pending acquisition of XIIDRA® and other ophthalmology assets.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
Rhea-AI Summary
Bausch + Lomb launches $1.4 billion offering of new senior secured notes and seeks incremental term loan facility for pending acquisition of XIIDRA. Bausch + Lomb expected to borrow $500 million under the Term Loan Facility. Notes offering not conditioned upon completion of the acquisition. Closing of the Term Loan Facility and Notes offering subject to market and other conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.44%
Tags
Bausch + Lomb Corp

NYSE:BLCO

BLCO Rankings

BLCO Stock Data

5.06B
40.40M
88.95%
11.28%
0.43%
Ophthalmic Goods Manufacturing
Manufacturing
Link
Canada
Vaughan

About BLCO

bausch and lomb corp is a renewables and environment company based out of calle laguna del marquesado nª 19, nave 16 edificio adriana 1ª planta, polígono industrial la resina (villaverde), madrid, community of madrid, spain.